Uncategorized

AAIC 2026: Lilly keeps door open for maintenance Kisunla after amyloid clearance

Published

on

Eli Lilly’s anti-amyloid Alzheimer’s drug is designed to be stopped after patients drop below a certain amyloid level in the brain. However, at the Alzheimer’s Association International Conference on Wednesday, Lilly revealed it is studying the potential of maintenance therapy for patients who need it.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version